Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab

Clinical and Molecular Allergy

Volumn 9, Issue , 2011, Pages

  Saavedra, Michael C ^a   Sur, Sanjiv ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOSPORIN; DIPHENHYDRAMINE; IMMUNOGLOBULIN E RECEPTOR; MONTELUKAST; OMALIZUMAB; PREDNISONE;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BASOPHIL; BLOOD SAMPLING; CASE REPORT; CHRONIC URTICARIA; CORTICOSTEROID THERAPY; DELAYED HYPERSENSITIVITY; DOWN REGULATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LONG TERM CARE; MEDICAL HISTORY; PSYCHOSIS; RECEPTOR AFFINITY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 78651483333     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/1476-7961-9-2     Document Type: Article

References (10)

1. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000, 105:664-72. 10.1067/mai.2000.105706, 10756214.
2. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004, 114:465-74. 10.1016/j.jaci.2004.02.049, 15356542.
3. Cebeci F, Tanrikut A, Topcu E, Onsun N, Kurtulmus N, Uras AR. Association between urticaria and thyroid autoimmunity. Eur J Dermatol 2006, 16(4):402-5.
4. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190. 10.1067/mai.2001.117880, 11496232.
5. Spector SL, Tan RA. Effects of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-3. 10.1016/S1081-1206(10)60644-8, 17718108.
6. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122:569-73. 10.1016/j.jaci.2008.07.006, 18774392.
7. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004, 113:297-302. 10.1016/j.jaci.2003.11.044, 14767445.
8. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti- IgE antibody. J Immunol 1997, 158:1438-45.
9. Beck LA, Marcotte GV, MacGlashan DW, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004, 114:527-30. 10.1016/j.jaci.2004.06.032, 15356552.
10. Galli SJ, Kawakami T. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002, 2:773-86. 10.1038/nri914, 12360215.